Physician profile
Michaela W Mcdonnell
NPI 1245348036
$6,376.86
in general payments reported to CMS, 2019-2025
33 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,633 · 2020: $798 · 2021: $1,196 · 2022: $1,286 · 2023: $804 · 2024: $540 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,461.52 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $536.79 | 2019-2024 | Winlevi, Blu-U, Odomzo |
| Allergan, INC. | $530.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $439.80 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $342.21 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $325.37 | 2019-2024 | Tremfya |
| Leo Pharma INC. | $300.97 | 2019-2024 | Adbry |
| Pfizer INC. | $296.61 | 2019-2023 | |
| Amgen INC. | $256.67 | 2019-2024 | Otezla |
| Lilly USA, LLC | $185.33 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $174.51 | 2019-2023 | |
| Galderma Laboratories, L.P. | $172.04 | 2019-2022 | |
| Incyte Corporation | $162.56 | 2021-2023 | Opzelura |
| Vyne Pharmaceuticals INC. | $159.33 | 2020-2021 | |
| Dusa Pharmaceuticals, INC. | $148.26 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $133.61 | 2021-2024 | Cimzia, Bimzelx |
| Epi Health, LLC | $103.33 | 2019 | |
| Mayne Pharma Commercial LLC | $88.53 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $76.99 | 2019-2023 | Jublia |
| Almirall LLC | $66.30 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.55 | 2022-2023 | Sotyktu |
| Organogenesis INC. | $57.30 | 2023-2024 | Puraply |
| Merz North America, INC. | $44.28 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $43.61 | 2019 | |
| Genentech USA, INC. | $35.28 | 2019 | |
| Celgene Corporation | $34.09 | 2019 | |
| Organon LLC | $28.18 | 2025 | |
| Dermira, INC. | $23.51 | 2019 | |
| Promius Pharma LLC | $22.15 | 2019 | |
| Kerecis Limited | $20.86 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Acera Surgical, INC. | $18.82 | 2022 | |
| Mission Pharmacal Company | $13.05 | 2019 | |
| Journey Medical Corporation | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Mcdonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.